Four things to know:
- Biogen is aiming to enroll more than 1,300 people with early Alzheimer’s in the study.
- The drugmaker plans to submit the study’s final protocol for review to the FDA in March, with patient screening beginning in May.
- Biogen predicts the study will take about four years to complete, meaning the drugmaker won’t have data until 2026.
- The study is a post-marketing requirement of the FDA’s accelerated approval pathway.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
